Show simple item record

dc.contributor.authorBeteck, Richard M.
dc.contributor.authorVan der Kooy, Frank
dc.contributor.authorLegoabe, Lesetja J.
dc.contributor.authorJordaan, Audrey
dc.contributor.authorSwart, Tarryn
dc.date.accessioned2020-08-06T13:56:25Z
dc.date.available2020-08-06T13:56:25Z
dc.date.issued2020
dc.identifier.citationBeteck, R.M. et al. 2020. 6-Nitro-1-benzylquinolones exhibiting specific antitubercular activity. Chemical biology & drug design, (In press). [https://doi.org/10.1111/cbdd.13747]en_US
dc.identifier.issn1747-0277
dc.identifier.issn1747-0285 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/35507
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/abs/10.1111/cbdd.13747
dc.identifier.urihttps://doi.org/10.1111/cbdd.13747
dc.description.abstractIn this study, we synthesized novel nitro quinolone‐based compounds and tested them in vitro against a panel of Gram‐positive and Gram‐negative pathogens including Mycobacterium tuberculosis (MTB), Pseudomonas aeruginosa , Acinetobacter baumannii , Klebsiella pneumonia , Staphylococcus aureus , and Escherichia coli for antibacterial activities and also against HeLa cells for overt cytotoxicity. Compound 8e was identified as a non‐toxic, potent hit with selective activity (MIC90 ˂ 0.24 µm ) against MTB. 8e , however, showed no activity against DprE1 mutant, suggesting DprE1 as the likely target for this compound classen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.subjectDprE1 enzymeen_US
dc.subjectMycobacterium tuberculosisen_US
dc.subjectNitro drugsen_US
dc.subjectQuinolonesen_US
dc.title6-Nitro-1-benzylquinolones exhibiting specific antitubercular activityen_US
dc.typeArticleen_US
dc.contributor.researchID25159194 - Beteck, Richard Mbi
dc.contributor.researchID34406786 - Van der Kooy, Frank
dc.contributor.researchID12902608 - Legoabe, Lesetja Jan


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record